# A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia

> **NCT02166814** · PHASE3 · COMPLETED · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 140 (actual)

## Conditions studied

- Essential Hypertension, Dyslipidemia

## Interventions

- **DRUG:** Fimasartan and Rosuvastatin
- **DRUG:** Fimasartan
- **DRUG:** Rosuvastatin

## Key facts

- **NCT ID:** NCT02166814
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2017-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02166814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02166814, "A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02166814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*